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Attention deﬁcit hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders of childhood and
adolescence. Classically, stimulants have been used in the treatment of this condition. Atomoxetine (Strattera; Eli Lilly and
Company) is a selective norepinephrine reuptake inhibitor (SNRI), one of the ﬁrst medications in the nonstimulant class of
medications that has been approved by the FDA for the treatment of ADHD. Atomoxetine is a phenoxypropylamine derivative
and is structurally related to the antidepressant ﬂuoxetine. The common side eﬀects reported with the use of atomoxetine include
mainly GI disturbances. Cardiovascular side eﬀects are less commonly reported. The increase in the noradrenergic tone may
explain some of the side eﬀects noted with the use of this medication. Here, we present a case of a patient who presented with
syncope, orthostatic hypotension, and tachycardia and discuss the various clinical implications based on the pharmacokinetics
and pharmacodynamics of the drug.
1.Introduction
Attention deﬁcit hyperactivity disorder (ADHD) is one of
the most common neurobehavioral disorders of childhood
and adolescence [1]. It isestimated to aﬀect5.29% ofschool-
aged children worldwide and is a problem that can continue
into adulthood, with signiﬁcant burden of disease on the
patient and the family’s lives [2]. Classically, stimulants
have been used in the treatment of this condition [3].
Atomoxetine (Strattera; Eli Lilly and Company) is a selective
norepinephrine reuptake inhibitor (SNRI), one of the ﬁrst
medications in the nonstimulant class of medications that
has been approved by the FDA for the treatment of at-
tention deﬁcit hyperactivity disorder [4]. “Atomoxetine is a
phenoxypropylamine derivative and is structurally related to
the antidepressant ﬂuoxetine” [5]. The common side eﬀects
reported with the use of atomoxetine include “headache, ab-
dominal pain, nausea, vomiting, decreased appetite, weight
loss, irritability, insomnia and sedation” [6]. Cardiovascular
side eﬀects are less commonly reported. The increase in the
noradrenergic tone may explain some of the side eﬀects
noted with the use of this medication. Here, we present a
case of a patient who presented with syncope, orthostatic
hypotension, and tachycardia and discuss the various clinical
implications based on the pharmacokinetics and pharmaco-
dynamics of the drug.
2.Case Report
A 26-years-old man with past medical history signiﬁcant for
mild mental retardation, obsessive compulsive disorder, and
attention deﬁcit hyperactivity disorder was admitted to our
service after falling at his workplace after rising from a chair.
It was a witnessed fall. Patient collapsed after rising from his
chairaftereatinglunchatwork.Therewasnourinary offecal
incontinence, no tongue biting, no jerky movements, and
no loss of consciousness. There was no confusion or altered
mental status afterwards.2 Case Reports in Medicine
However, interestingly, the patient was tachycardic from
120s to 140s on presentation and was also noted to have
orthostatic hypotension, despite IV hydration in the ED.
Of note, patient’s intake has always been good and rather
he enjoys drinking plenty of ﬂuids. The review of systems
was negative, and the patient did not have any other signs
or symptoms concerning any infection. Physical exam was
signiﬁcant only for mildly dilated pupils.
Electrocardiogram (ECG) revealed sinus tachycardia,
with no ST changes, and QTc interval was noted to be within
the normal limits. Echocardiography showed a normal left
ventricular size with mild hypertrophy with a low normal
systolic function (ejection fraction of 50–55%). Segmental
LV function was normal. Right ventricular size and function
were normal, and no valvular abnormalities were noted. A
head CT done in the emergency department also did not
reveal any masses or lesions, and there were no fractures or
hematomas. Thyroid studies were also within normal limits.
As per the patient’s parent, who has been taking care of
him for the past 26 years, the patient has never had these
symptoms. The patient apparently has been on atomoxetine
(Strattera; Eli Lilly and Company), for the last 6 years
without any problems. When asked about any new changes
or additions to his medications, the patient was recently
started on ﬂuoxetine (Prozac) couple of months ago to help
him with the “tic” of picking at his face.
The tachycardia, orthostatic hypotension, and the syn-
cope were new and important. Given no organic problems
to explain his symptoms, we reviewed the side eﬀects proﬁle
of atomoxetine and any potential drug interactions with
ﬂuoxetine, since the symptoms temporally correlated with
the onset of the new drug. Interestingly, as discussed below,
ﬂuoxetinedoes aﬀectthemetabolism ofatomoxetinecausing
drug levels of the latter to rise by several folds. Following is
an account of the cardiovascular side eﬀects of atomoxetine
(Strattera) with a discussion on clinical implications and
ways forward.
3.Discussion
Table 1 outlines some of the common cardiovascular side ef-
fects noted with the use of atomoxetine. Increase in the heart
rate and blood pressure appears to be dose dependent and
the eﬀects decrease with the cessation of therapy [8].
As noted in a recent review by Hammerness and col-
leagues, “serious cardiovascular side eﬀects have not been
noted in trials with therapeutic doses of atomoxetine” [4].
Usually, the increase in heart rate was estimated to be be-
tween 5 and 9 beats. However, in a report of 5 large placebo-
controlled clinical trials of612 patients, 3.6% of children/ad-
olescents had a rise in their heart rate of at least 25 beats per
minute or heart rate >110 [8].
With respect to orthostatic hypotension and syncope, “in
child and adolescent trials, 0.2% (12/5596)of strattera-treat-
ed patients experienced orthostatic hypotension and 0.8%
(46/5596) experienced syncope. In short-term child and ad-
olescent-controlled trials, 1.8% (6/340) of strattera-treated
patientsexperienced orthostatic hypotensioncompared with
Table 1: Cardiovascular side eﬀects of atomoxetine (Strattera) [1,
2, 5, 7].
Common side eﬀects
Increase in heart rate
Sinus tachycardia
Increase in systolic pressure especially in adults
Increase in diastolic blood pressure especially in children
Palpitations
Less common/case reports
Prolongationof QT interval
Orthostatic hypotension
Raynaud’s phenomenon
Syncope
Chest pain
Sudden death
0.5% (1/207) of placebo-treated patients. Syncope was not
reported during short-term child and adolescent placebo-
controlled ADHD trials” [7].
Moreover, from the clinical standpoint, there are 3 im-
portant considerations that we wanted to highlight in pa-
tients who are on long-term treatment with this drug.
Firstly,thedrugismainly metabolizedbythecytochrome
P450 system (CYP2D6), and genetically people can have dif-
ferentialactivity oftheenzyme,hence,theterms“poormeta-
bolizers” (PM) and “extensive metabolizers” (EM). It is esti-
mated that approximately 7% of the Caucasian population
may be poor metabolizers, leading to slow metabolism (5.2
v e r s u s2 2h o u r si nP Mv e r s u sE M )a n dh i g h e rd r u gl e v e l s
(estimated 5 times higher) [9]. Genetic testing is available at
various centers and may be considered in select patients who
may need to be on long-termtherapy with the medication or
in individualswho start exhibiting serioussideeﬀectsdespite
being on therapeutic doses.
Secondly, often at times, especially now with polyphar-
macy becoming increasingly common, potential drug inter-
actions are easily forgotten. With the advent of newer drugs
coming into the market, this aspect of clinical care would be
of paramount importance. In this speciﬁc case, inhibitors of
the cytochrome P450 (CYP2D6) (outlined in Table 2)c a n
increase drug levels by several folds [10] and may account
for the new onset of symptoms in a patient who previously
was tolerating the medication without any problems. The
pharmacokinetic proﬁle of patients who are on drugs that
inhibit the cytochrome P450 (CYP2D6) is seen to resemble
that of patients who are “poor metabolizers” [10].
Thirdly, there have been case reports of QT interval pro-
longation with the use of this drug, which may lead to life-
threatening arrythmias and may account for the cases of
sudden cardiac death reported with the use of the drug.
Based on these reports, in vitro studies on guinae pig cardiac
myocytes and human embryonic kidney cells, Scherer and
colleagues were able to identify a molecular basis for the
side eﬀect noted [5]. The SNRI atomoxetine apparentlyCase Reports in Medicine 3
Table 2: Some of the commonly used drugs that inhibit the Cyto-
chrome P450 (CYP2D6) system [3, 6, 7].
Fluoxetine
Paroxetine
Quinidine
Citalopram
Escitalopram
Bupropion
Sertraline
Chlorpromazine
Hydroxyzine
Clomipramine
inhibits hERG-potassium channels, leading to prolongation
of the QT interval. Though the eﬀect is mild at therapeutic
concentrations, this should be considered in patients who
are poor metabolizers, are on inhibitors of the cytochrome
system, or exhibit side eﬀects related to drug overdose. ECGs
shouldalso bedoneperiodicallyin patientsonlong-termuse
of this drug, and the drug should be avoided in patients with
preexisting cardiac problems or conditions that may make
them prone to arrhythmias [11].
In our patient, after discussion with the patient’s psychi-
atrist, we discontinued patient’s ﬂuoxetine since it was not
helping his symptoms of “tic”for which it was started earlier.
With respect to his atomoxetine, we held it for a few days
following which patient would be restarted on a lower dose
for now with close followup and/or potentially otheroptions
[7]. Previous studies have also reported the cardiovascular
side eﬀects seemed to resolve with the discontinuation of
the medication [6]. As per prescribing information from
the manufacturer’s website, the maximum adult daily dose
recommended is not more than 100 mg per day, with
dosage adjustment in patients with hepatic impairment and
presence of a strong CYP2D6 inhibitor and patients known
to be poor metabolizers. The addition of ﬂuoxetine (20mg)
to our patient’s medication regimen (100mg daily) without
adjustment of doses most likely led to supratherapeutic drug
levels, explaining the side eﬀects experienced by our patient.
Patients who need to be on atomoxetine need to have
frequent monitoring of their cardiovascular symptoms on
their follow-up visits (measuring blood pressure and heart
rate at each visit and EKG if there are any concerns), along
with an eye on potential drug interactions before starting
any new medication that might aﬀect the metabolism of
the drug. Studies into the molecular basis of the drug are
revealing newer insights explaining the cardiovascular side
eﬀect proﬁle of the medication.
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